Table 1.
Baseline characteristics of the study participants.
| Characteristic | Pembrolizumab (N=101) | Sintilimab (N=63) | P value |
|---|---|---|---|
| Median age (range), years | 65 (55-74) | 65 (57-72) | |
| Age, years | 0.246 | ||
| ≥65 | 54(53.5%) | 27(42.9%) | |
| <65 | 47(46.5%) | 36(57.1%) | |
| Sex | 0.484 | ||
| Male | 94 (93.1%) | 61 (96.8%) | |
| Female | 7 (6.9%) | 2 (3.2%) | |
| Smoking history | 0.089 | ||
| Never | 29 (28.7%) | 9 (14.3%) | |
| Current | 5 (5.0%) | 3 (4.8%) | |
| Past | 67 (66.3%) | 51 (81.0%) | |
| Stage | 0.744 | ||
| IIIB/IIIC | 16 (15.8%) | 8 (12.7%) | |
| IV | 85 (84.2%) | 55 (87.3%) | |
| Family History | 0.563 | ||
| Yes | 25 (24.7%) | 19 (30.2%) | |
| No | 76 (73.3%) | 44 (69.8%) | |
| Metastasis | 0.311 | ||
| Brain | 10 (9.9%) | 3 (4.8%) | |
| Bone | 16 (15.8%) | 16 (25.4%) | |
| Liver | 7 (6.9%) | 5 (7.9%) | |
| Adrenal gland | 9 (8.9%) | 3 (4.8%) | |
| Pleural | 6 (5.9%) | 6 (9.5%) | |
| PD-L1 expression | 0.455 | ||
| Not examined | 48 (47.5%) | 37 (58.7%) | |
| <1% | 17 (16.8%) | 7 (11.1%) | |
| ≥1% | 36(35.6%) | 19(30.1%) | |
| 1%-49% | 26 (25.7%) | 12 (19.0%) | |
| ≥50% | 10 (9.9%) | 7 (11.1%) | |
| Combination of chemotherapy | |||
| Gemcitabine+Cisplatin | 5(5.0%) | 3(5.0%) | |
| Gemcitabine+Carboplatin | 2(2.0%) | 0 | |
| Paclitaxel+Cisplatin | 74(73.3%) | 42(66.7%) | |
| Paclitaxel+Carboplatin | 20(19.8%) | 18(28.6%) | |
| Combination of radiotherapy | 0.867 | ||
| Yes | 20 (19.8%) | 11 (17.5%) | |
| No | 81 (80.2%) | 52 (82.5%) |